Farmer Jocelyn R, Ong Mei-Sing, Barmettler Sara, Yonker Lael M, Fuleihan Ramsay, Sullivan Kathleen E, Cunningham-Rundles Charlotte, Walter Jolan E
Massachusetts General Hospital, Boston, MA, United States.
Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA, United States.
Front Immunol. 2018 Jan 9;8:1740. doi: 10.3389/fimmu.2017.01740. eCollection 2017.
Common variable immunodeficiency (CVID) is increasingly recognized for its association with autoimmune and inflammatory complications. Despite recent advances in immunophenotypic and genetic discovery, clinical care of CVID remains limited by our inability to accurately model risk for non-infectious disease development. Herein, we demonstrate the utility of unbiased network clustering as a novel method to analyze inter-relationships between non-infectious disease outcomes in CVID using databases at the United States Immunodeficiency Network (USIDNET), the centralized immunodeficiency registry of the United States, and Partners, a tertiary care network in Boston, MA, USA, with a shared electronic medical record amenable to natural language processing. Immunophenotypes were comparable in terms of native antibody deficiencies, low titer response to pneumococcus, and B cell maturation arrest. However, recorded non-infectious disease outcomes were more substantial in the Partners cohort across the spectrum of lymphoproliferation, cytopenias, autoimmunity, atopy, and malignancy. Using unbiased network clustering to analyze 34 non-infectious disease outcomes in the Partners cohort, we further identified unique patterns of lymphoproliferative (two clusters), autoimmune (two clusters), and atopic (one cluster) disease that were defined as CVID non-infectious endotypes according to discrete and non-overlapping immunophenotypes. Markers were both previously described {high serum IgE in the atopic cluster [odds ratio (OR) 6.5] and low class-switched memory B cells in the total lymphoproliferative cluster (OR 9.2)} and novel [low serum C3 in the total lymphoproliferative cluster (OR 5.1)]. Mortality risk in the Partners cohort was significantly associated with individual non-infectious disease outcomes as well as lymphoproliferative cluster 2, specifically (OR 5.9). In contrast, unbiased network clustering failed to associate known comorbidities in the adult USIDNET cohort. Together, these data suggest that unbiased network clustering can be used in CVID to redefine non-infectious disease inter-relationships; however, applicability may be limited to datasets well annotated through mechanisms such as natural language processing. The lymphoproliferative, autoimmune, and atopic Partners CVID endotypes herein described can be used moving forward to streamline genetic and biomarker discovery and to facilitate early screening and intervention in CVID patients at highest risk for autoimmune and inflammatory progression.
普通可变免疫缺陷(CVID)因其与自身免疫性和炎症性并发症的关联而越来越受到认可。尽管在免疫表型和基因发现方面取得了最新进展,但由于我们无法准确模拟非感染性疾病发展的风险,CVID的临床护理仍然有限。在此,我们展示了无偏网络聚类作为一种新方法的实用性,该方法使用美国免疫缺陷网络(USIDNET)的数据库、美国的中央免疫缺陷登记处以及美国马萨诸塞州波士顿的三级医疗网络Partners(其共享适合自然语言处理的电子病历)来分析CVID中非感染性疾病结局之间的相互关系。在天然抗体缺陷、对肺炎球菌的低滴度反应和B细胞成熟停滞方面,免疫表型具有可比性。然而,在Partners队列中,记录的非感染性疾病结局在淋巴增殖、血细胞减少、自身免疫、特应性和恶性肿瘤等方面更为显著。使用无偏网络聚类分析Partners队列中的34种非感染性疾病结局,我们进一步确定了淋巴增殖性(两个聚类)、自身免疫性(两个聚类)和特应性(一个聚类)疾病的独特模式,这些模式根据离散且不重叠的免疫表型被定义为CVID非感染性内型。标志物既有先前描述的 {特应性聚类中的高血清IgE [优势比(OR)6.5] 和总淋巴增殖性聚类中的低类别转换记忆B细胞(OR 9.2)},也有新发现的 [总淋巴增殖性聚类中的低血清C3(OR 5.1)]。Partners队列中的死亡风险与个体非感染性疾病结局以及淋巴增殖性聚类2显著相关,特别是(OR 5.9)。相比之下,无偏网络聚类未能将成人USIDNET队列中的已知合并症联系起来。总之,这些数据表明无偏网络聚类可用于CVID中重新定义非感染性疾病的相互关系;然而,其适用性可能仅限于通过自然语言处理等机制充分注释的数据集。本文描述的Partners CVID淋巴增殖性、自身免疫性和特应性内型可用于简化基因和生物标志物的发现,并促进对自身免疫和炎症进展风险最高的CVID患者进行早期筛查和干预。